Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV versus intra-arterial fotemustine in liver metastases from uveal melanoma
2004-002245-12Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fotemustine in intraocular melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Sep 2004; status: terminated.
02
Drugs
fotemustine
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2004-002245-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002245-12.